Japanese phase III study of Lonasen in adolescents with schizophrenia meets primary endpoint July 23, 2019
Acadia reports phase III topline results on pimavanserin as adjunctive treatment for schizophrenia July 23, 2019
Metabolic disorder and neuroinflammation alleviated by novel CB1 receptor antagonist in AD models July 23, 2019
ACCORDANCE study of AP-CD/LD does not achieve statistical superiority on the primary endpoint July 23, 2019
Inactivation of RBPJ leads to improper communication in brain pericytes and vascular malformations July 22, 2019
RSS